As of Sep 30
| +0.91 / +3.54%|
The 3 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 22.00, with a high estimate of 26.00 and a low estimate of 18.00. The median estimate represents a -17.32% decrease from the last price of 26.61.
The current consensus among 4 polled investment analysts is to Hold stock in Enanta Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.